Method for producing γδt cell

JP2024096899A5Active Publication Date: 2024-11-01KYOTO UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024065962
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-06-25
Filing Date
2024-04-16
Publication Date
2024-11-01
Estimated Expiration
2039-07-12

AI Technical Summary

Technical Problem

There is a lack of efficient methods for producing γδT cells from stem cells, which are crucial for immune cell therapy due to their cytotoxic activity against cancer cells, and existing methods do not provide stable supply.

Method used

A method is developed to produce γδT cells by inducing pluripotent stem cells from cells other than αβT cells, incorporating a chimeric antigen receptor (CAR) gene to enhance cytotoxicity, and introducing a fusion protein containing IL-15 and IL-15Rα, resulting in high cytotoxic activity against cancer cells.

Benefits of technology

The method enables the efficient production of γδT cells with high cytotoxic activity against cancer cells, demonstrating strong cytotoxicity in vitro and in vivo, making them suitable for cancer therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000031_0000
    Figure 00000031_0000
  • Figure 00000031_0001
    Figure 00000031_0001
  • Figure 00000031_0002
    Figure 00000031_0002
Patent Text Reader

Abstract

To provide a method for producing γδT cells from induced pluripotent stem cells.SOLUTION: There is provided a method for producing γδT cells from induced pluripotent stem cells, in which the induced pluripotent stem cells are derived from cells other than αβT cells. The method comprises the following steps of: (1) establishing induced pluripotent stem cells from cells other than αβT cells; and (2) differentiating the induced pluripotent stem cells established in the step (1) into T cells.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for producing γδ T cells from induced pluripotent stem cells, γδ T cells differentiated from induced pluripotent stem cells, and a cell population containing said cells.

[0002] BACKGROUND OF THEINVENTION In recent years, immune cell therapy has been attracting attention as a treatment for cancer. Immune cell therapy is a treatment in which immune cells that have been proliferated and activated outside the patient's body are administered to the patient and the immune cells attack cancer cells. Immune cell therapy has the advantage of having almost no side effects compared to the three major conventional therapies of surgery, radiation therapy, and chemotherapy. There are various types of immune cell therapy, but one that has attracted attention is treatment using γδ T cells, which are responsible for natural immunity and have cytotoxic activity against cancer cells.

[0003] In order to realize γδ T cell therapy, it is desirable to develop a manufacturing method for efficiently producing and stably supplying the cells. Although a method for selecting only γδ T cells in a patient's blood (a method for culturing blood cells in a medium containing zoledronic acid and IL-2 (Patent Document 1)) is known, to the inventors' knowledge, no method for producing γδ T cells from stem cells has been reported. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2006 / 006720 Brochure Summary of the Invention [Problem to be solved by the invention]

[0005] An objective of the present invention is to provide a method for producing γδ T cells from stem cells. Another objective of the present invention is to provide γδ T cells differentiated from stem cells and a cell population comprising said cells. [Means for solving the problem]

[0006] The present inventors conducted intensive research to solve the above problems, and found that γδ T cells can be efficiently obtained by inducing induced pluripotent stem cells from cells other than αβ T cells and then inducing the cells to T cells. In addition, when a chimeric antigen receptor (CAR) gene was introduced into the γδ T cells obtained in this way to produce γδ T cells expressing the CAR, it was shown that the γδ T cells exhibited high cytotoxicity against cancer cells that were difficult to recognize and damage by the γδ T cells before the introduction. Based on these findings, the present inventors conducted further research and completed the present invention.

[0007] That is, the present invention provides the following. [1] A method for producing γδ T cells from induced pluripotent stem cells, wherein the induced pluripotent stem cells are derived from cells other than αβ T cells. [2] The method according to [1], comprising the steps of: (1) A process for establishing induced pluripotent stem cells from cells other than αβ T cells. (2) Differentiating the induced pluripotent stem cells established in step (1) into T cells. [3] The method according to [1] or [2], wherein the cells other than αβ T cells are mononuclear cells other than αβ T cells. [4] The method according to any one of [1] to [3], wherein the cells other than αβ T cells are monocytes. [5] A method for detecting and binding to a tumor-specific antigen or a tumor-associated antigen in a cell obtained in any one of steps (1) and (2) above. (i) a nucleic acid encoding an αTCR and a nucleic acid encoding a βTCR; (ii) a nucleic acid encoding a γTCR and a nucleic acid encoding a δTCR, and / or (iii) A method according to any one of [2] to [4], comprising a step of introducing a nucleic acid encoding a CAR. [6] The method according to [5], wherein the γTCR is Vγ9TCR and the δTCR is Vδ2TCR. [7] The method according to any one of [1] to [6], comprising a step of introducing a nucleic acid encoding a fusion protein comprising IL-15 and IL-15Rα into a cell obtained in any one of steps (1) and (2). [8] A gamma delta T cell derived from an induced pluripotent stem cell, wherein the induced pluripotent stem cell is derived from a cell other than an alpha beta T cell. [9] A gamma delta T cell produced by the method described in any one of [1] to [7].

[10] The cell described in [8] or [9], wherein the cell other than an αβ T cell is a mononuclear cell other than an αβ T cell.

[11] The cell described in any one of [8] to

[10] , wherein the cell other than an αβ T cell is a monocyte.

[12] The cell described in any one of [8] to

[11] , wherein the γδ T cell expresses Vγ9 TCR and Vδ2 TCR.

[13] The cell described in any one of [8] to

[12] , wherein the γδ T cell expresses a CAR.

[14] The cell described in any one of [8] to

[13] , wherein the γδ T cell expresses a fusion protein comprising IL-15 and IL-15Rα.

[15] A cell population, in which at least 90% or more of the total cells are γδ T cells, the γδ T cells being cells differentiated from induced pluripotent stem cells derived from cells other than αβ T cells.

[16] A pharmaceutical comprising a cell according to any one of [8] to

[14] or a cell population according to

[15] .

[17] The pharmaceutical composition according to

[16] for use in the prevention or treatment of a tumor.

[18] A cell-killing agent comprising a cell according to any one of [8] to

[14] or a cell population according to

[15] .

[19] A cell according to any one of [8] to

[14] or a cell population according to

[15] for use in the prevention or treatment of a tumor.

[20] Use of a cell according to any one of [8] to

[14] or a cell population according to

[15] in the manufacture of a preventive or therapeutic agent for a tumor.

[21] A method for preventing or treating a tumor, comprising administering a cell according to any one of [8] to

[14] or a cell population according to

[15] . Effect of the Invention

[0008] According to the present invention, it is possible to provide a method for producing γδ T cells from induced pluripotent stem cells, γδ T cells differentiated from induced pluripotent stem cells, and a cell population containing said cells. Furthermore, among the γδ T cells produced by the above method, cells expressing a chimeric antigen receptor (CAR) can exhibit high cytotoxic activity in vitro and in vivo, specific to the antigen recognized by the CAR. [Brief description of the drawings]

[0009] [Figure 1] Figure 1 shows the results of staining the acquired cells using an antibody set (Vδ1 Myltenyi FITC, Vδ2 Myltenyi APC, γδ TCR BD BV510, CD3 BioLegend APC / Cy7, and αβ TCR eBioscience FITC). The filled peaks show the results of the unstained group, and the blank peaks show the results of staining using each antigen-specific antibody. [Diagram 2] Figure 2 shows the results of flow cytometry staining of acquired cells using a set of antibodies (V51 Myltenyi FITC, V52 Myltenyi APC, γδTCR BD BV510, CD3 BioLegend APC / Cy7 and αβTCR eBioscience FITC). [Diagram 3] 3 shows the results of measuring the cytotoxic activity of the obtained γδ T cells. The vertical axis shows cytotoxic activity (%), and the horizontal axis shows the ratio of the number of mixed γδ T cells to the number of target cells. [Figure 4] 4 shows the results of measuring cell proliferation of iPS cell-derived γδ T cells (iγδ T cells). The vertical axis indicates the cell proliferation rate, and the horizontal axis indicates the number of days since the start of stimulation with anti-CD3 antibody (UCHT1) and anti-CD30 antibody. [Diagram 5]FIG. 5 shows the expression of CD3 and γδTCR molecules on the cell membrane surface of γδT cells (iγ9δ2T cells) differentiated by introducing the Vγ9Vδ2TCR gene into iPS cells. [Figure 6] FIG. 6 shows the expression of CD3 and γδTCR molecules on the cell membrane surface of γδT cells (iHγ9δ2T cells) differentiated from iPS cell-derived hematopoietic progenitor cells (HPCs) by introducing the Vγ9Vδ2TCR gene. [Figure 7] 7 shows the results of measuring cell proliferation of iγδ T cells expressing the anti-CD19-CAR gene (iCD19CAR / IL-15γδ T cells). The vertical axis shows the number of cells, and the horizontal axis shows the number of days since the start of stimulation with anti-CD3 antibody (UCHT1) and anti-CD30 antibody. [Figure 8] 8 shows the results of measuring cell proliferation of iHγ9δ2T cells expressing the anti-CD19-CAR gene (iHCD19CAR / IL-15γ9δ2T). The vertical axis shows the number of cells, and the horizontal axis shows the number of days since the start of stimulation with an anti-CD3 antibody (UCHT1). [Figure 9] 9 shows the results of measuring the cytotoxic activity of iγδ T cells expressing the anti-CD19-CAR gene (iCD19CAR / IL-15γδ T cells). The vertical axis shows the target cell cytotoxicity rate (%), and the horizontal axis shows the ratio of the number of mixed iCD19CAR / IL-15γδ T cells to the number of target cells. [Figure 10] 10 shows the results of measuring the cytotoxic activity of iHγ9δ2 T cells expressing anti-CD19-CAR genes (iHCD19CAR / IL-15γ9δ2 T cells). The vertical axis shows the target cell cytotoxicity rate (%), and the horizontal axis shows the ratio of the number of mixed iHCD19CAR / IL-15γ9δ2 T cells to the number of target cells. [Figure 11] Figure 11 shows the effect of in vivo administration of iγδ T cells expressing anti-CD19-CAR gene (iCD19CAR / IL-15γδ T cells) on the survival time of human CD19-positive tumor-bearing mice. The vertical axis shows the survival rate of the mice, and the horizontal axis shows the number of days since the day of cancer cell transplantation. [Figure 12]Figure 12 shows the antitumor effect of in vivo administration of iHγ9δ2T cells expressing the anti-CD19-CAR gene (iHCD19CAR / IL-15γ9δ2T) on luciferase-expressing human tumor-implanted mice.

[0010] Detailed Description of the Invention As used herein, "gene expression" includes both the synthesis of mRNA from a specific nucleotide sequence of the gene (also referred to as transcription or mRNA expression) and the synthesis of a protein based on the information in the mRNA (also referred to as translation or protein expression); unless otherwise specified, "gene expression" or simply "expression" refers to protein expression.

[0011] As used herein, "positive" means that the protein or mRNA is expressed in a detectable amount by a method known in the art. Protein detection can be performed using an immunological assay using an antibody, such as ELISA, immunostaining, or flow cytometry. In addition, in the case of a protein that is expressed intracellularly and not present on the cell surface (e.g., a transcription factor or a subunit thereof), a reporter protein is expressed together with the protein, and the target protein can be detected by detecting the reporter protein. mRNA detection can be performed using a nucleic acid amplification method and / or a nucleic acid detection method, such as RT-PCR, microarray, biochip, and RNAseq.

[0012] As used herein, "negative" means that the expression level of the protein or mRNA is below the lower limit of detection by all or any of the above known techniques. The lower limit of detection of the expression of the protein or mRNA may vary depending on the technique.

[0013] In this specification, a positive result is also referred to as "there is expression of a protein or mRNA," and a negative result is also referred to as "there is no expression of a protein or mRNA." Therefore, adjusting the "presence or absence of expression" means that the expression level of the target protein or mRNA is set to either a state where the expression level is equal to or higher than the lower limit of detection (positive) or a state where the expression level is lower than the lower limit of detection (negative).

[0014] As used herein, "culture" refers to maintaining, propagating (growing) and / or differentiating cells in an in vitro environment. "Culturing" means maintaining, propagating (growing) and / or differentiating cells outside a tissue or outside the body, for example, in a cell culture plate, dish or flask.

[0015] As used herein, "enriching" refers to increasing the proportion of a particular component in a composition, such as a composition of cells, and "enriched," when used to describe a composition of cells, e.g., a cell population, refers to a cell population in which the amount of a particular component is increased compared to the proportion of such component in the cell population prior to enrichment. For example, a composition, such as a cell population, can be enriched for a target cell type, and thus the proportion of the target cell type is increased compared to the proportion of target cells present in the cell population prior to enrichment. A cell population can also be enriched for a target cell type by cell selection and sorting methods known in the art. A cell population can also be enriched by certain culture methods, sorting or selection processes described herein. In certain embodiments of the invention, a method of enriching a target cell population enriches the cell population for the target cell population by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97%, 98% or 99%.

[0016] As used herein, "expansion culture" refers to culturing for the purpose of proliferating a desired cell population and increasing the number of cells. The increase in cell number may be achieved by the increase in cell number due to cell proliferation exceeding the decrease in cell number due to cell death, and it is not necessary for all cells in the cell population to proliferate. The increase in cell number may be 1.1-fold, 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 30-fold, 40-fold, 50-fold, 100-fold, 300-fold, 500-fold, 1000-fold, 3000-fold, 5000-fold, 10000-fold, 100000-fold, or 1000000-fold or more compared to before the start of expansion culture.

[0017] As used herein, the term "stimulation" refers to the binding of a substance to various receptors and the like to activate downstream signal pathways.

[0018] As used herein, a "cell population" refers to two or more cells of the same or different types. A "cell population" also refers to a mass of cells of the same or different types.

[0019] 1. Method for producing γδ T cells from induced pluripotent stem cells The present invention provides a method for producing γδ T cells from induced pluripotent stem cells and a cell population containing the γδ T cells (hereinafter abbreviated as "the method of the present invention"). The method of the present invention comprises a step of differentiating induced pluripotent stem cells into T cells. The induced pluripotent stem cells used in the method of the present invention may be cells that have already been established and stocked, or may be induced pluripotent stem cells established from cells other than αβ T cells. Thus, in one embodiment of the present invention, the method of the present invention comprises (1) a step of establishing induced pluripotent stem cells from cells other than αβ T cells, and (2) a step of differentiating the induced pluripotent stem cells established in step (1) into T cells.

[0020] In the present invention, the term "T cell receptor (TCR)" refers to a dimer of TCR chains (α chain, β chain, γ chain, δ chain). The term "γδ T cell" refers to a cell that expresses CD3 and expresses a TCR (hereinafter, sometimes referred to as "γδ TCR") composed of a TCR γ chain (γ TCR) and a TCR δ chain (δ TCR). The term "αβ T cell" refers to a cell that expresses CD3 and expresses a TCR (hereinafter, sometimes referred to as "αβ TCR") composed of a TCR α chain (α TCR) and a TCR β chain (β TCR). Most αβ T cells recognize antigen peptide-MHC (major histocompatibility complex, in humans, HLA: human leukocyte antigen) complexes with αβ TCR (this is called MHC restriction). In contrast, γδ T cells recognize various molecules expressed by cells with γδ TCR, regardless of MHC molecules. Each TCR chain is composed of a variable region and a constant region, and the variable region has three complementarity determining regions (CDR1, CDR2, CDR3). The TCR gene is composed of many V (variable), D (diversity), J (joining), and C (constant) gene fragments on the genome. Gene rearrangement occurs during the differentiation and maturation of T cells, and in the β chain gene, one D and one J are randomly selected and joined, followed by gene rearrangement between the V-DJ. During this process, random insertions and deletions of bases occur between the VD and DJ, increasing gene diversity. In the TCR mRNA precursor, RNA splicing occurs in the VDJ region and the common region, the C region, and it is expressed as a functional TCR gene.

[0021] Examples of γTCR include Vγ1TCR, Vγ2TCR, Vγ3TCR, Vγ4TCR, Vγ5TCR, Vγ6TCR, Vγ7TCR, Vγ8TCR, and Vγ9TCR, and examples of δTCR include Vδ1TCR, Vδ2TCR, Vδ3TCR, Vδ4TCR, Vδ5TCR, Vδ6TCR, Vδ7TCR, Vδ8TCR, and Vδ9TCR. Specific combinations of γTCR and δTCR include, but are not limited to, Vγ3Vδ1TCR, Vγ4Vδ1TCR, Vγ9Vδ1TCR, and Vγ9Vδ2TCR.

[0022] (1) Establishing induced pluripotent stem cells In the present invention, "induced pluripotent stem cells" (hereinafter sometimes referred to as "iPS cells") refer to stem cells that are established by introducing reprogramming factors into somatic cells, have pluripotency that allows them to differentiate into many cells present in the body, and also have the ability to proliferate, and include at least any cell that can be induced into the hematopoietic progenitor cells used in the present invention. The induced pluripotent stem cells are preferably derived from mammals (e.g., mice, rats, hamsters, guinea pigs, dogs, monkeys, orangutans, chimpanzees, and humans), and more preferably from humans.

[0023] The method of establishing artificial pluripotent stem cells is known in the art, and can be established by introducing reprogramming factors into any somatic cells. Here, the reprogramming factors include, for example, genes or gene products such as Oct3 / 4, Sox2, Sox1, Sox3, Sox15, Sox17, Klf4, Klf2, c-Myc, N-Myc, L-Myc, Nanog, Lin28, Fbx15, ERas, ECAT15-2, Tcl1, beta-catenin, Lin28b, Sall1, Sall4, Esrrb, Nr5a2, Tbx3 or Glis1, and these reprogramming factors can be used alone or in combination. Combinations of reprogramming factors include WO2007 / 069666, WO2008 / 118820, WO2009 / 007852, WO2009 / 032194, WO2009 / 058413, WO2009 / 057831, WO2009 / 075119, WO2009 / 079007, WO2009 / 091659, WO2009 / 101084, WO2009 / 101407, WO2009 / 102983, WO2009 / 114949, WO2009 / 117439, WO2009 / 126250, WO2009 / 126251, WO 2009 / 126655, WO2009 / 157593, WO2010 / 009015, WO2010 / 033906, WO2010 / 033920, WO2010 / 042800, WO2010 / 050626, WO2010 / 056831, WO2010 / 0689 55, WO2010 / 098419, WO2010 / 102267, WO2010 / 111409, WO2010 / 111422, WO2010 / 115050, WO2010 / 124290, WO2010 / 147395, WO2010 / 147612, Huangfu D, et al. (2008), Nat. Biotechnol., 26: 795-797, Shi Y, et al. (2008), Cell Stem Cell, 2: 525-528, Eminli S, et al. (2008), Stem Cells. 26:2467-2474, Huangfu D, et al. (2008), Nat. Biotechnol. 26:1269-1275, Shi Y, et al.(2008), Cell Stem Cell, 3, 568-574、Zhao Y, et al. (2008), Cell Stem Cell, 3:475-479、Marson A, (2008), Cell Stem Cell, 3, 132-135、Feng B, et al. (2009), Nat. Cell Biol. 11:197-203、RL Judson et al., (2009), Nat. Biotechnol., 27:459-461、Lyssiotis CA, et al. (2009), Proc Natl Acad Sci US A. 106:8912-8917、Kim JB, et al. (2009), Nature. 461:649-643, Ichida JK, et al. (2009), Cell Stem Cell. 5:491-503、Heng JC, et al. (2010), Cell Stem Cell. 6:167-74、Han J, et al. (2010), Nature. 463:1096-100、Mali P, et al. (2010), Stem Cells. 28:713-720, Maekawa M, et al. (2011), Nature. 474:225-9.

[0024] Somatic cells include, but are not limited to, fetal (baby) somatic cells, neonatal (baby) somatic cells, and mature somatic cells, as well as primary culture cells, passaged cells, and established cell lines. Furthermore, the aforementioned cells may be healthy cells or diseased cells. Specifically, examples of somatic cells include differentiated cells such as (1) tissue stem cells (somatic stem cells) such as neural stem cells, hematopoietic progenitor cells, mesenchymal stem cells, and dental pulp stem cells, (2) tissue progenitor cells, and (3) blood cells (e.g., peripheral blood cells, umbilical cord blood cells, etc.), mononuclear cells (e.g., lymphocytes (NK cells, B cells, T cells other than αβT cells (e.g., γδT cells, etc.), monocytes, dendritic cells, etc.)), granulocytes (e.g., eosinophils, neutrophils, basophils), megakaryocytes), epithelial cells, endothelial cells, muscle cells, fibroblasts (e.g., skin cells, etc.), hair cells, hepatic cells, gastric mucosa cells, intestinal cells, spleen cells, pancreatic cells (e.g., exocrine pancreatic cells, etc.), brain cells, lung cells, kidney cells, and adipocytes. Among these, mononuclear cells other than αβT cells are preferred, and more specifically, monocytes or γδT cells are preferred.

[0025] When the reprogramming factor is in the form of DNA, the reprogramming factor can be introduced into somatic cells by, for example, calcium phosphate coprecipitation, PEG, electroporation, microinjection, lipofection, etc. For example, the methods described in Cell Engineering Special Issue 8, New Cell Engineering Experimental Protocols, 263-267 (1995) (published by Shujunsha), Virology, vol. 52, 456 (1973), and Folia Pharmacol. Jpn., vol. 119 (No. 6), 345-351 (2002), etc. can be used. When a viral vector is used, the nucleic acid can be introduced into a suitable packaging cell (e.g., Plat-E cell) or a complementing cell line (e.g., 293 cell), the viral vector produced in the culture supernatant is collected, and the vector can be introduced into the cell by infecting the cell with the vector by a method appropriate for each viral vector. For example, specific means using a retroviral vector as a vector are disclosed in International Publication No. 2007 / 69666, Cell, 126, 663-676 (2006), and Cell, 131, 861-872 (2007), etc. In particular, when a retroviral vector is used, highly efficient gene transfer into various cells is possible by using a recombinant fibronectin fragment, CH-296 (manufactured by Takara Bio Inc.).

[0026] The reprogramming factor may be directly introduced into cells in the form of RNA, and the reprogramming factor may be expressed in cells. The method of introducing RNA may be a known method, for example, lipofection method or electroporation method. In addition, when the reprogramming factor is in the form of protein, it may be introduced into cells by lipofection, fusion with cell membrane permeable peptide (for example, TAT and polyarginine derived from HIV), microinjection, or other methods.

[0027] Examples of basal media include Dulbecco's medium (e.g., IMDM), Eagle's medium (e.g., DMEM, EMEM, BME, MEM, αMEM), Ham's medium (e.g., F10 medium, F12 medium), RPMI medium (e.g., RPMI-1640 medium, RPMI-1630 medium), MCDB medium (e.g., MCDB104, 107, 131, 151, 153 medium), Fischer's medium, 199 medium, medium for primate ES cells (culture medium for primate ES / iPS cells, ReproCell), medium for mouse ES cells (TX-WES culture medium, ThromboX), serum-free medium (mTeSR, Stemcell Examples of suitable medium include, but are not limited to, StemSpan (registered trademark) SFEM, StemSpan (registered trademark) H3000, Stemline II, ESF-B medium, ESF-C medium, CSTI-7 medium, Neurobasal medium (Life Technologies), StemPro-34 medium, and StemFit (registered trademark) (e.g., StemFit AK03N, StemFit AK02N). Furthermore, these media can be mixed and used as necessary, and examples of such media include DMEM / F12 medium.

[0028] The basal medium may be appropriately supplemented with 10% to 20% serum (fetal bovine serum (FBS), human serum, horse serum) or serum substitutes (KSR, etc.), insulin, various vitamins, L-glutamine, various amino acids such as non-essential amino acids, 2-mercaptoethanol, various cytokines (interleukins (IL-2, IL-7, IL-15, etc.), stem cell factor (SCF), activin, etc.), various hormones, various growth factors (leukemia inhibitory factor (LIF), basic fibroblast growth factor (bFGF), TGF-β, etc.), various extracellular matrices, various cell adhesion molecules, antibiotics such as penicillin / streptomycin and puromycin, pH indicators such as phenol red, and the like.

[0029] The culture is preferably carried out, for example, in an atmosphere of 1% to 10%, preferably 2% to 5% CO2, at about 37°C to 42°C, preferably about 37°C to 39°C, for about 25 to 50 days.

[0030] In the present invention, the mammal from which the somatic cells are collected is not particularly limited, but is preferably a human. From the viewpoint of preventing rejection, autologous cells, allogeneic cells having the same or substantially the same HLA type, allogeneic cells in which the presence or absence of HLA expression and / or the expression level is adjusted, etc. are preferred. As for HLA, it is preferred that the presence or absence of expression and / or the expression level of at least some of the subunits contained in class I and / or class II are adjusted.

[0031] (2) Differentiating induced pluripotent stem cells into T cells The method for differentiating induced pluripotent stem cells into T cells is not particularly limited as long as it can differentiate induced pluripotent stem cells into γδ T cells. In one embodiment of the present invention, the step of differentiating induced pluripotent stem cells into T cells may comprise: (2-1) a step of differentiating the induced pluripotent stem cells into hematopoietic progenitor cells; and (2-2) a step of differentiating the hematopoietic progenitor cells into CD3-positive T cells.

[0032] (2-1) Differentiating induced pluripotent stem cells into hematopoietic progenitor cells In the present invention, "hematopoietic progenitor cell(s) (HPC)" refers to CD34 positive cells, preferably CD34 / CD43 positive (DP) cells. In the present invention, hematopoietic progenitor cells and hematopoietic stem cells are not distinguished from each other and refer to the same cell unless otherwise specified.

[0033] The method for differentiating induced pluripotent stem cells into hematopoietic progenitor cells is not particularly limited as long as it is capable of differentiating into hematopoietic progenitor cells. For example, there may be mentioned a method of culturing pluripotent stem cells in an induction medium for hematopoietic progenitor cells, as described in WO 2013 / 075222, WO 2016 / 076415, and Liu S. et al., Cytotherapy, 17 (2015); 344-358.

[0034] In the present invention, the induction medium for hematopoietic progenitor cells is not particularly limited, and a medium used for culturing animal cells can be prepared as the basal medium. Examples of the basal medium include those used in the above step (1). The medium may contain serum or may be used serum-free. If necessary, the basal medium may contain, for example, vitamin C (e.g., ascorbic acid), albumin, insulin, transferrin, selenium compounds (e.g., sodium selenite), fatty acids, trace elements, 2-mercaptoethanol, thioglycerol (e.g., α-monothioglycerol (MTG)), lipids, amino acids, L-glutamine, L-alanyl-L-glutamine (e.g., Glutamax (registered trademark)), non-essential amino acids, vitamins, growth factors, low molecular weight compounds, antibiotics (e.g., penicillin, streptomycin), antioxidants, pyruvic acid, buffers, inorganic salts, cytokines, etc.

[0035] In the present invention, vitamin C means L-ascorbic acid and its derivatives, and L-ascorbic acid derivatives means those which become vitamin C by enzymatic reaction in vivo. Examples of the ascorbic acid derivatives used in the present invention include vitamin C phosphate (e.g., ascorbic acid 2-phosphate), ascorbic acid glucoside, ascorbyl ethyl, vitamin C ester, ascorbyl tetrahexyldecanoate, ascorbyl stearate, and ascorbyl-2-phosphate-6 palmitate. Vitamin C phosphate (e.g., ascorbic acid 2-phosphate) is preferred, and examples thereof include L-ascorbyl phosphate salts such as sodium L-ascorbate phosphate or magnesium L-ascorbate phosphate.

[0036] When vitamin C is used, it is preferable to add (supplement) vitamin C every 4 days, every 3 days, every 2 days, or every day, and more preferable to add every day. In one embodiment, the vitamin C is added in an amount equivalent to 5 ng / ml to 500 ng / ml in the culture solution (e.g., an amount equivalent to 5 ng / ml, 10 ng / ml, 25 ng / ml, 50 ng / ml, 100 ng / ml, 200 ng / ml, 300 ng / ml, 400 ng / ml, or 500 ng / ml). In another embodiment, the vitamin C is added in an amount equivalent to 5 μg / ml to 500 μg / ml in the culture medium (e.g., an amount equivalent to 5 μg / ml, 10 μg / ml, 25 μg / ml, 50 μg / ml, 100 μg / ml, 200 μg / ml, 300 μg / ml, 400 μg / ml, or 500 μg / ml).

[0037] The medium used in step (2-1) may further contain at least one cytokine selected from the group consisting of BMP4 (bone morphogenetic protein 4), VEGF (vascular endothelial growth factor), SCF (stem cell factor), TPO (thrombopoietin), FLT-3L (Flt3 Ligand), and bFGF (basic fibroblast growth factor). More preferably, the medium is a culture to which BMP4, VEGF, and bFGF are added, and even more preferably, the medium is a culture to which BMP4, VEGF, SCF, and bFGF are added.

[0038] When cytokines are used, their concentrations in the culture medium can be, for example, 5 ng / ml to 500 ng / ml for BMP4, 5 ng / ml to 500 ng / ml for VEGF, 5 ng / ml to 100 ng / ml for SCF, 1 ng / ml to 100 ng / ml for TPO, 1 ng / ml to 100 ng / ml for FLT-3L, and 5 ng / ml to 500 ng / ml for bFGF.

[0039] The medium may be supplemented with a TGFβ inhibitor. The TGFβ inhibitor is a small molecule inhibitor that interferes with the signal transduction of the TGFβ family, and includes, for example, SB431542, SB202190 (RK Lindemann et al., Mol. Cancer 2:20(2003)), SB505124 (GlaxoSmithKline), NPC30345, SD093, SD908, SD208 (Scios), LY2109761, LY364947, LY580276 (Lilly Research Laboratories), etc. For example, when the TGFβ inhibitor is SB431542, the concentration in the medium is preferably 0.5 μM to 100 μM.

[0040] The culture of induced pluripotent stem cells may be adhesion culture or suspension culture. In the case of adhesion culture, it may be performed using a culture vessel coated with an extracellular matrix component, or may be co-cultured with feeder cells. The feeder cells are not particularly limited, but examples thereof include fibroblasts (mouse embryonic fibroblasts (MEF), mouse fibroblasts (STO), etc.). It is preferable that the feeder cells are inactivated by a method known per se, for example, irradiation with radiation (such as gamma rays) or treatment with an anticancer drug (such as mitomycin C). Examples of the extracellular matrix components include fibrous proteins such as matrigel (Niwa A, et al. PLoS One.6(7):e22261, 2011), gelatin, collagen, and elastin, glycosaminoglycans and proteoglycans such as hyaluronic acid and chondroitin sulfate, and cell adhesive proteins such as fibronectin, vitronectin, and laminin.

[0041] Suspension culture is a method of culturing cells in a non-adherent state to a culture vessel, and can be performed using, but is not limited to, a culture vessel that has not been artificially treated (e.g., coated with extracellular matrix, etc.) to improve adhesion to cells, or a culture vessel that has been artificially treated to suppress adhesion (e.g., coated with polyhydroxyethyl methacrylate (poly-HEMA) or nonionic surface-active polyol (Pluronic F-127, etc.)). In suspension culture, it is preferable to form embryoid bodies (EBs) and then culture them.

[0042] In the present invention, hematopoietic progenitor cells can also be prepared from a net-like structure (also called ES-sac or iPS-sac) obtained by culturing pluripotent stem cells. Here, the term "net-like structure" refers to a three-dimensional sac-like structure (with an internal space) derived from pluripotent stem cells, which is formed from an endothelial cell population or the like and contains hematopoietic progenitor cells inside.

[0043] The culture temperature condition is not particularly limited, but is, for example, about 37°C to 42°C, preferably about 37°C to 39°C. In addition, a person skilled in the art can appropriately determine the culture period while monitoring the number of hematopoietic progenitor cells. As long as hematopoietic progenitor cells are obtained, the number of days is not particularly limited, but is, for example, at least 6 days or more, 7 days or more, 8 days or more, 9 days or more, 10 days or more, 11 days or more, 12 days or more, 13 days or more, 14 days or more, and preferably 14 days. A long culture period is usually not a problem in the production of hematopoietic progenitor cells, but is, for example, preferably 35 days or less, more preferably 21 days or less. In addition, the culture may be performed under a hypoxic condition, and in the present invention, the hypoxic condition is, for example, an oxygen concentration of 15%, 10%, 9%, 8%, 7%, 6%, 5%, or less.

[0044] (2-2) Differentiating hematopoietic progenitor cells into CD3-positive T cells The method for differentiating hematopoietic progenitor cells into CD3-positive T cells is not particularly limited as long as it can differentiate hematopoietic progenitor cells into CD3-positive T cells. Examples of the method include a method of culturing hematopoietic progenitor cells under culture conditions similar to those for inducing T cells from hematopoietic progenitor cells, as described in WO 2016 / 076415 or WO 2017 / 221975.

[0045] In the present invention, the medium for inducing differentiation into CD3-positive T cells is not particularly limited, and a medium used for culturing animal cells can be prepared as the basal medium. Examples of the basal medium include the same as those used in the above step (1). The medium may contain serum or may be used serum-free. If necessary, the basal medium may contain, for example, vitamin C (e.g., ascorbic acid), albumin, insulin, transferrin, selenium compounds (e.g., sodium selenite), fatty acids, trace elements, 2-mercaptoethanol, thioglycerol (e.g., α-monothioglycerol (MTG)), lipids, amino acids, L-glutamine, L-alanyl-L-glutamine (e.g., Glutamax (registered trademark)), non-essential amino acids, vitamins, growth factors, low molecular weight compounds, antibiotics (e.g., penicillin, streptomycin), antioxidants, pyruvic acid, buffers, inorganic salts, cytokines, etc.

[0046] When vitamin C is used in step (2-2), the vitamin C may be the same as those described in step (2-1) and may be added in the same manner. In one embodiment, the concentration of vitamin C in the medium or culture solution is preferably 5 μg / ml to 200 μg / ml. In another embodiment, the vitamin C is added in an amount equivalent to 5 μg / ml to 500 μg / ml in the culture solution (e.g., an amount equivalent to 5 μg / ml, 10 μg / ml, 25 μg / ml, 50 μg / ml, 100 μg / ml, 200 μg / ml, 300 μg / ml, 400 μg / ml, or 500 μg / ml).

[0047] In step (2-2), it is preferable to use a p38 inhibitor and / or SDF-1 (stromal cell-derived factor 1). In the present invention, the term "p38 inhibitor" refers to a substance that inhibits the function of p38 protein (p38 MAP kinase), and examples thereof include, but are not limited to, chemical inhibitors of p38, dominant-negative mutants of p38, or nucleic acids encoding the same.

[0048] Examples of chemical inhibitors of p38 used in the present invention include, but are not limited to, SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(4-pyridyl)-1H-imidazole) and derivatives thereof, SB202190 (4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole) and derivatives thereof, SB239063 (trans-4-[4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]cyclohexanol) and derivatives thereof, SB220025 and derivatives thereof, PD169316, RPR200765A, AMG-548, BIRB-796, SClO-469, SCIO-323, VX-702, and FR167653. These compounds are commercially available, for example, SB203580, SB202190, SC239063, SB220025 and PD169316 from Calbiochem, and SCIO-469 and SCIO-323 from Scios. Preferred chemical inhibitors of P38 include SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(4-pyridyl)-1H-imidazole) and its derivatives.

[0049] The dominant negative mutant of p38 used in the present invention includes p38T180A in which threonine at position 180 located in the DNA binding region of p38 is point mutated to alanine, and p38Y182F in which tyrosine at position 182 of human and mouse p38 is point mutated to phenylalanine. The p38 inhibitor is contained in the medium in the range of about 1 μM to about 50 μM. When SB203580 is used as the p38 inhibitor, it can be contained in the medium in the range of 1 μM to 50 μM, 5 μM to 30 μM, or 10 μM to 20 μM.

[0050] The SDF-1 used in the present invention may be not only SDF-1α or its mature form, but also isoforms such as SDF-1β, SDF-1γ, SDF-1δ, SDF-1ε, or SDF-1φ, or their mature forms, or may be a mixture of these in any ratio. Preferably, SDF-1α is used. SDF-1 may also be called CXCL-12 or PBSF.

[0051] In the present invention, SDF-1 may have one or several amino acids substituted, deleted, added, and / or inserted in its amino acid sequence, so long as it has activity as a chemokine (SDF-1 with such amino acid substitution, deletion, addition, and / or insertion is also called "SDF-1 mutant"). Similarly, sugar chains may be substituted, deleted, and / or added in SDF-1 or SDF-1 mutant. Examples of the SDF-1 mutant include those that retain at least four cysteine ​​residues (Cys30, Cys32, Cys55, and Cys71 in the case of human SDF-1α) and have 90% or more identity to the amino acid sequence of the natural form, but are not limited to these amino acid mutations. SDF-1 may be from a mammal, such as a human, or a non-human mammal, such as a monkey, sheep, cow, horse, pig, dog, cat, rabbit, rat, or mouse. For example, the protein registered under GenBank registration number NP_954637 can be used as human SDF-1α, and the protein registered under GenBank registration number NP_000600 can be used as SDF-1β.

[0052] SDF-1 may be commercially available, may be purified from nature, or may be produced by peptide synthesis or genetic engineering. SDF-1 is contained in the medium, for example, in the range of about 10 ng / ml to about 100 ng / ml. Alternatively, SDF-1 substitutes having SDF-1-like activity may be used instead of SDF-1. Examples of such SDF-1 substitutes include CXCR4 agonists, and low molecular weight compounds having CXCR4 agonist activity may be added to the medium instead of SDF-1.

[0053] The medium used in step (2-2) may further contain at least one, preferably all, of cytokines selected from the group consisting of SCF, TPO (thrombopoietin), FLT-3L, and IL-7. The concentrations of these cytokines are, for example, 10 ng / ml to 100 ng / ml for SCF, 10 ng / ml to 200 ng / ml for TPO, 1 ng / ml to 100 ng / ml for IL-7, and 1 ng / ml to 100 ng / ml for FLT-3L.

[0054] In step (2-2), the hematopoietic progenitor cells may be cultured in an adherent or floating state. In the case of the adherent culture, the culture vessel may be coated and used, or the hematopoietic progenitor cells may be co-cultured with feeder cells or the like. An example of the feeder cells to be co-cultured is bone marrow stromal cell line OP9 cells (available from Riken BioResource Center). The OP9 cells are preferably OP9-DL4 cells or OP9-DL1 cells that constitutively express DLL4 or DLL1 (e.g., Holmes R1 and Zuniga-Pflucker JC. Cold Spring Harb Protoc. 2009(2)). In the present invention, when OP9 cells are used as feeder cells, they may be appropriately added to the medium with separately prepared DLL4 or DLL1, or a fusion protein of DLL4 or DLL1 with Fc or the like. When feeder cells are used, it is preferable to appropriately replace the feeder cells and perform the culture. The replacement of the feeder cells can be performed by transferring the target cells being cultured onto the feeder cells that have been seeded in advance. The replacement can be performed every 5 days, 4 days, 3 days, or 2 days. When embryoid bodies are cultured in suspension to obtain hematopoietic progenitor cells, it is preferable to dissociate them into single cells and then perform adhesion culture. Co-culture with feeder cells is possible, but it is preferable to perform culture without using feeder cells. In the case of adhesion culture, examples of coating agents for coating a culture vessel include Matrigel (Niwa A, et al. PLos One, 6(7):e22261, 2011), collagen, gelatin, laminin, heparan sulfate proteoglycan, RetroNectin (registered trademark), DLL4 or DLL1, or a fusion protein of DLL4 or DLL1 with an Fc region of an antibody (hereinafter sometimes referred to as Fc) (e.g., DLL4 / Fc chimera), entactin, and / or a combination thereof, with a combination of RetroNectin and a fusion protein of DLL4 with Fc or the like being preferred.

[0055] In step (2-2), the culture temperature conditions are not particularly limited, but for example, about 37°C to about 42°C, preferably about 37°C to about 39°C. Furthermore, those skilled in the art can appropriately determine the culture period while monitoring the number of γδ T cells, etc. As long as γδ T cells are obtained, the number of days is not particularly limited, but is typically at least 10 days or more, 12 days or more, 14 days or more, 16 days or more, 18 days or more, or 20 days or more, and preferably 21 days. Furthermore, 90 days or less is preferable, and 42 days or less is more preferable.

[0056] The CD3 positive T cell population obtained by the above steps contains γδ T cells, and step (2) may further include the following step (2-3).

[0057] (2-3) A step of enriching CD3 positive T cells The method for enriching CD3-positive T cells is not particularly limited as long as γδ T cells are enriched. For example, there may be mentioned a method of culturing CD3-positive T cells under culture conditions similar to those used in the process of inducing CD8-positive T cells from CD4CD8-positive T cells, as described in WO 2016 / 076415 and WO 2017 / 221975.

[0058] In the present invention, the medium used for enriching CD3-positive T cells is not particularly limited, and a medium used for culturing animal cells can be prepared as the basal medium. Examples of the basal medium include the same as those used in the above step (1). The medium may contain serum or may be used serum-free. If necessary, the basal medium may contain, for example, vitamin C (e.g., ascorbic acid), albumin, insulin, transferrin, selenium compounds (e.g., sodium selenite), fatty acids, trace elements, 2-mercaptoethanol, thioglycerol (e.g., α-monothioglycerol (MTG)), lipids, amino acids, L-glutamine, L-alanyl-L-glutamine (e.g., Glutamax (registered trademark)), non-essential amino acids, vitamins, growth factors, low molecular weight compounds, antibiotics (e.g., penicillin, streptomycin), antioxidants, pyruvic acid, buffers, inorganic salts, cytokines, hormones, etc. In one embodiment of the present invention, vitamin C such as ascorbic acid, insulin, transferrin, selenium compounds (eg, sodium selenite), and cytokines such as IL-7 may be contained.

[0059] When vitamin C is used in step (2-3), the vitamin C may be the same as those described in step (2-1) and may be added in the same manner. In one embodiment, the concentration of vitamin C in the medium or culture solution is preferably 5 μg / ml to 200 μg / ml. In another embodiment, the vitamin C is added in an amount equivalent to 5 μg / ml to 500 μg / ml in the culture solution (e.g., an amount equivalent to 5 μg / ml, 10 μg / ml, 25 μg / ml, 50 μg / ml, 100 μg / ml, 200 μg / ml, 300 μg / ml, 400 μg / ml, or 500 μg / ml).

[0060] When a hormone is used in step (2-3), the hormone may be an adrenal cortical hormone. The adrenal cortical hormone is a glucocorticoid or a derivative thereof, and examples thereof include cortisone acetate, hydrocortisone, fludrocortisone acetate, prednisolone, triamcinolone, methylprednisolone, dexamethasone, betamethasone, and beclomethasone propionate. Dexamethasone is preferable. When the adrenal cortical hormone is dexamethasone, its concentration in the medium is 1 nM to 100 nM.

[0061] In step (2-3), a CD3 / TCR complex agonist is contained in the medium. The CD3 / TCR complex agonist is not particularly limited as long as it is a molecule capable of transmitting a signal from the CD3 / TCR complex into the CD3-positive cell by specifically binding to the CD3 / TCR complex. Examples of the CD3 / TCR complex agonist include a CD3 agonist and / or a TCR agonist. Examples of the CD3 agonist include an anti-CD3 agonist antibody (also simply referred to as an "anti-CD3 antibody") or a binding fragment thereof, and examples of the TCR agonist include at least one selected from the group consisting of an anti-TCR agonist antibody (also simply referred to as an "anti-TCR antibody") or a binding fragment thereof, an MHC / antigen peptide complex or a multimer thereof, and an MHC / superantigen complex or a multimer thereof. When an anti-CD3 antibody is used, the anti-CD3 antibody includes both a polyclonal antibody and a monoclonal antibody, but is preferably a monoclonal antibody. The antibody may belong to any immunoglobulin class, IgG, IgA, IgM, IgD or IgE, but is preferably IgG. Examples of anti-CD3 antibodies include an antibody (OKT3) produced from the OKT3 clone and an antibody (UCHT1) produced from the UCHT1 clone, and is preferably UCHT1. The concentration of the anti-CD3 antibody in the medium is, for example, 10 ng / ml to 1000 ng / ml, preferably 50 ng / ml to 800 ng / ml, and more preferably 250 ng / ml to 600 ng / ml. The CD3 / TCR complex agonist may be a commercially available product, may be purified from nature, or may be produced by peptide synthesis, genetic engineering or chemical synthesis. For example, OKT3 and UCHT1 can be purchased from ThermoFisher, GeneTex, etc.

[0062] When a cytokine is used in step (2-3), examples of the cytokine include IL-2 and IL-7. When the cytokine is IL-2, its concentration in the medium is 10 U / ml to 1000 U / mL, and when the cytokine is IL-7, its concentration in the medium is 1 ng / ml to 1000 ng / mL.

[0063] In step (2-3), the culture temperature conditions are not particularly limited, but for example, about 37°C to about 42°C, preferably about 37°C to about 39°C. Furthermore, those skilled in the art can appropriately determine the culture period while monitoring the number of γδ T cells, etc. The number of days is not particularly limited as long as γδ T cells are obtained, but is, for example, at least 1 day or more, 2 days or more, 3 days or more, 4 days or more, 5 days or more, preferably 6 days. Furthermore, 28 days or less is preferable, and 14 days or less is more preferable.

[0064] The CD3-positive T cell population obtained by the above steps contains γδ T cells and can be further enriched, and step (2) may further include the following steps (2-4).

[0065] (2-4) Expanding and culturing CD3-positive T cells including γδ T cells The method for expanding CD3-positive T cells, including γδ T cells, is not particularly limited as long as the γδ T cells proliferate. For example, there is a method for culturing CD3-positive T cells, including γδ T cells, under culture conditions similar to those used in the process of expanding CD8α+β+ cytotoxic T cells, as described in WO 2016 / 076415 and WO 2018 / 135646.

[0066] In the present invention, the medium used for the expansion of CD3 positive T cells including γδ T cells is not particularly limited, and a medium used for culturing animal cells can be prepared as the basal medium. Examples of the basal medium include the same as those used in the above step (2-3). The medium may contain serum or may be used serum-free. If necessary, the basal medium may contain, for example, vitamin C (e.g., ascorbic acid), albumin, insulin, transferrin, selenium compounds (e.g., sodium selenite), fatty acids, trace elements, 2-mercaptoethanol, thioglycerol (e.g., α-monothioglycerol (MTG)), lipids, amino acids, L-glutamine, L-alanyl-L-glutamine (e.g., Glutamax (registered trademark)), non-essential amino acids, vitamins, growth factors, low molecular weight compounds, antibiotics (e.g., penicillin, streptomycin), antioxidants, pyruvic acid, buffers, inorganic salts, cytokines, hormones, etc. In one embodiment of the present invention, vitamin C such as ascorbic acid, insulin, transferrin, selenium compounds (eg, sodium selenite), and cytokines such as IL-7 may be contained.

[0067] When vitamin C is used in step (2-4), the vitamin C may be the same as those described in step (2-1) and may be added in the same manner. In one embodiment, the concentration of vitamin C in the medium or culture solution is preferably 5 μg / ml to 200 μg / ml. In another embodiment, the vitamin C is added in an amount equivalent to 5 μg / ml to 500 μg / ml in the culture solution (e.g., an amount equivalent to 5 μg / ml, 10 μg / ml, 25 μg / ml, 50 μg / ml, 100 μg / ml, 200 μg / ml, 300 μg / ml, 400 μg / ml, or 500 μg / ml).

[0068] In step (2-4), a CD3 / TCR complex agonist is contained in the medium. The CD3 / TCR complex agonist is not particularly limited as long as it is a molecule capable of transmitting a signal from the CD3 / TCR complex into the CD3-positive cell by specifically binding to the CD3 / TCR complex. Examples of the CD3 / TCR complex agonist include a CD3 agonist and / or a TCR agonist. Examples of the CD3 agonist include an anti-CD3 agonist antibody (also simply referred to as an "anti-CD3 antibody") or a binding fragment thereof, and examples of the TCR agonist include at least one selected from the group consisting of an anti-TCR agonist antibody (also simply referred to as an "anti-TCR antibody") or a binding fragment thereof, an MHC / antigen peptide complex or a multimer thereof, and an MHC / superantigen complex or a multimer thereof. When an anti-CD3 antibody is used, the anti-CD3 antibody includes both a polyclonal antibody and a monoclonal antibody, but is preferably a monoclonal antibody. The antibody may belong to any of the immunoglobulin classes IgG, IgA, IgM, IgD, or IgE, but is preferably IgG. Examples of anti-CD3 antibodies include an antibody (OKT3) produced from the OKT3 clone and an antibody (UCHT1) produced from the UCHT1 clone, and is preferably UCHT1. The concentration of the anti-CD3 antibody in the medium is, for example, 0.3 ng / ml to 10,000 ng / ml, preferably 50 ng / ml to 5,000 ng / ml, and more preferably 200 ng / ml to 4,000 ng / ml. The CD3 / TCR complex agonist may be a commercially available product, may be purified from nature, or may be produced by peptide synthesis, genetic engineering, or chemical synthesis. For example, OKT3 and UCHT1 can be purchased from ThermoFisher, GeneTex, and the like.

[0069] In step (2-4), it is preferable that fibronectin or a variant thereof is present in the medium. Such fibronectin is not particularly limited as long as it is a molecule capable of binding to CD3-positive cells. The variant of fibronectin is not particularly limited as long as it is a molecule capable of binding to VLA-5 and VLA-4 on the surface of CD3-positive cells, and an example of such a variant is retronectin. Fibronectin or a variant thereof may be present in any manner in the medium. For example, it may be contained in the medium during culture, or may be immobilized on a culture vessel, but is preferably immobilized on a culture vessel.

[0070] When fibronectin or a variant thereof is contained in the medium, the medium may be the same as the medium containing the CD3 / TCR complex agonist. In addition, the presence or absence of serum, additives, etc. may be the same as the medium containing the CD3 / TCR complex agonist. When fibronectin or a variant thereof is contained in the medium, the concentration of fibronectin or a variant thereof may be 10 ng / ml or more as the lower limit, preferably 100 ng / ml or more, and 10000 μg / ml or less as the upper limit, preferably 1000 μg / ml or less.

[0071] In step (2-4), it is also preferable that a CD30 agonist is present in the medium. Such a CD30 agonist is not particularly limited as long as it is a molecule that can transmit a signal from CD30 into the cell by specifically binding to CD30. Examples of the CD30 agonist include at least one selected from the group consisting of an anti-CD30 agonist antibody (also simply referred to as an "anti-CD30 antibody") or a binding fragment thereof, and a CD30 ligand or a binding fragment thereof.

[0072] The CD30 agonist used in step (2-4) may be present in any form as long as it is capable of contacting CD30 during culture, similar to the CD3 / TCR complex agonist. For example, it may be contained in the medium during culture or may be immobilized on a culture vessel, but is preferably contained in the medium.

[0073] When the CD30 agonist is contained in the medium, the medium may be the same as the medium containing the CD3 / TCR complex agonist. In addition, the presence or absence of serum, additives, etc. may be the same as the medium containing the CD3 / TCR complex agonist. When the CD30 agonist is contained in the medium, the concentration of the CD30 agonist in the medium may be appropriately determined by those skilled in the art depending on the CD30 agonist. For example, when the CD30 agonist is an anti-CD30 agonist antibody or a binding fragment thereof, the concentration of the anti-CD30 agonist antibody or a binding fragment thereof in the medium is usually 1 ng / ml to 10000 ng / ml, preferably 30 ng / ml to 300 ng / ml.

[0074] In addition, when the CD30 agonist is solid-phased in the culture vessel, the culture vessel may be the same as the culture vessel in which the CD3 / TCR complex agonist is solid-phased. In addition, the method of solidifying the CD30 agonist in the culture vessel may be the same as the method of solidifying the CD30 agonist in the culture vessel. The concentration of the CD30 agonist solution when solidifying the CD30 agonist in the culture vessel may be 0.1 ng / ml or more as the lower limit, preferably 1 ng / ml or more, and 10000 ng / ml or less as the upper limit, preferably 1000 ng / ml or less.

[0075] When a cytokine is used in step (2-4), examples of the cytokine include IL-2, IL-7, IL-12, IL-15, IL-18, IL-21, etc., and one or more of these (preferably all of them) may be used. When the cytokine is IL-2, its concentration in the medium may be 10 U / ml to 1000 U / ml, and when the cytokine is IL-7, its concentration in the medium may be 1 ng / ml to 1000 ng / ml. In addition, the concentration of IL-12 in the medium may be 5 ng / ml to 500 ng / ml, the concentration of IL-15 in the medium may be 1 ng / ml to 100 ng / ml, the concentration of IL-18 in the medium may be 5 ng / ml to 500 ng / ml, and the concentration of IL-21 in the medium may be 2 ng / ml to 200 ng / ml.

[0076] In step (2-4), the medium may further contain a TNF family cytokine as a cytokine. Examples of TNF family cytokines include TNF-α, TNF-β, lymphotoxin α, Fas ligand, TRAIL, TWEAK, TL1A, RANK ligand, OX40 ligand, APRIL, AITRL, BAFF, 4-1BBL, and CD40 ligand, and TL1A is preferred. When TL1A is used, its concentration in the medium may be 5 ng / ml to 500 ng / ml, preferably 10 ng / ml to 300 ng / ml, and more preferably 20 ng / ml to 200 ng / ml.

[0077] In step (2-4), the medium may further contain an apoptosis inhibitor. Examples of the apoptosis inhibitor include protease inhibitors, such as caspase inhibitors. A preferred caspase inhibitor is Pan Caspase FMK inhibitor Z-VAD (N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethylketone) (hereinafter sometimes referred to as "Z-VAD-FMK"), and the concentration of the inhibitor in the medium may be 1 μM to 1000 μM, preferably 1 μM to 500 μM, more preferably 1 μM to 200 μM, and particularly preferably 1 μM to 50 μM.

[0078] In the present invention, the obtained γδ T cells may be isolated and used, or may be used as is (i.e., as a cell population that may contain other cell types). When isolating, the cells can be isolated using at least one molecule selected from the group consisting of γTCR, δTCR, and CD3 as an indicator, and the isolation method can be a method well known to those skilled in the art. For example, the isolation method includes, but is not limited to, a method of isolating by flow cytometry or magnetic cell separation using antibodies against γTCR, δTCR, and CD3 (bound to magnetic beads, etc., as necessary), and a method of purifying using an affinity column on which a desired antigen is immobilized, etc. When used as is, the proportion of γδ T cells in a cell population may be increased using a method well known to those skilled in the art. Methods for increasing the proportion of γδ T cells in a cell population include, but are not limited to, those described in Front. Immunol., 5:636 (2014), JP2017-537625, and JP2003-529363.

[0079] In addition, the cells used in the method of the present invention may have a nucleic acid encoding an exogenous TCR and / or chimeric antigen receptor (CAR) that recognizes and binds to an antigen or the antigen-HLA complex. Thus, in one embodiment of the present invention, the method may include a step of introducing a nucleic acid encoding the TCR (i.e., (i) αTCR and βTCR, (ii) γTCR and δTCR) and / or (iii) a nucleic acid encoding the CAR into a cell (e.g., pluripotent stem cell, hematopoietic progenitor cell, etc.) obtained at any time during the step of (1) establishing an induced pluripotent stem cell from a cell other than αβT cell, and (2) differentiating the induced pluripotent stem cell established in step (1) into a T cell. Among these, the nucleic acid encoding the (i) αTCR and βTCR is introduced into a γδT cell obtained during any step of the step of differentiating the induced pluripotent stem cell into a T cell. In the present specification, the nucleic acid encoding the TCR means a nucleic acid containing a base sequence encoding one chain forming a TCR and a base sequence encoding the other chain. Furthermore, the nucleic acid encoding a TCR also means a combination of a nucleic acid containing a base sequence encoding one of the chains forming a TCR and a nucleic acid containing a base sequence encoding the other chain. That is, when a nucleic acid encoding a TCR ((i) αTCR and βTCR) is introduced into a cell, a single nucleic acid containing both a base sequence encoding an αTCR and a base sequence encoding a βTCR may be introduced, or a nucleic acid containing a base sequence encoding an αTCR and a base sequence encoding a βTCR may be introduced separately. When introduced separately, these nucleic acids may be introduced simultaneously or sequentially. The same applies to (ii) γTCR and δTCR.

[0080] The TCR used in the present invention includes not only TCRs in which the α and β chains of the TCR form a heterodimer (i.e., αβTCR) or TCRs in which the γ and δ chains of the TCR form a heterodimer (i.e., γδTCR), but also TCRs in which homodimers form. Furthermore, TCRs in which a part or all of the constant region is deleted or whose amino acid sequence is recombined may be used. Among these, γδTCR is preferred, and Vγ9Vδ2TCR is particularly preferred.

[0081] Furthermore, the constant region of the TCR chain of the cytotoxic T cell (CTL) clone from which it is derived may be modified in a specific manner, for example, by substituting a specific amino acid residue in the constant region of the TCR of the CTL clone with a cysteine ​​residue to enhance the efficiency of dimer expression due to disulfide bonds between the TCR chains, but this modification is not limited thereto.

[0082] The antigen targeted by the TCR includes, but is not limited to, a tumor antigen. The tumor antigen may be a tumor-specific antigen (TSA) or a tumor-associated antigen (TAA). Specific examples of such tumor antigens include one or more antigens selected from the group consisting of differentiation antigens such as MART-1 / MelanA (MART-I), gp100 (Pmel 17), tyrosinase, TRP-1, and TRP-2; tumor-specific multilineage antigens such as WT1, Glypican-3, MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, and p15; fetal antigens such as CEA; overexpressed tumor genes or mutated tumor suppressor genes such as p53, Ras, and HER-2 / neu; unique tumor antigens resulting from chromosomal translocations such as BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, and MYL-RAR; and viral antigens such as the Epstein-Barr virus antigen EBVA and the human papillomavirus (HPV) antigens E6 and E7. Other tumor antigens include TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY-ESO, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, β-catenin, CDK4, Mum-1, p 15, p 16, 43-9F, 5T4, 791Tgp72, α-fetoprotein, β-HCG, BCA225, BTAA, CA 125, CA 15-3\CA 27.29\BCAA, CA 195, CA 242, CA-50, CAM43, CD68\P1, CO-029, FGF-5, G250, Ga733\EpCAM, HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB / 70K, NY-CO-1, RCAS1, SDCCAG16, TA-90\Mac-2 binding protein\cyclophilin C-related protein, TAAL6, TAG72, TLP and TPS.

[0083] As shown in the examples below, in one embodiment, among the γδ T cells obtained by the method of the present invention, cells expressing a chimeric antigen receptor (CAR) exhibited specific cytotoxic activity and antitumor activity (also referred to simply as "cytotoxic activity" in this specification) against cells expressing the target antigen of CAR. Therefore, from the viewpoint of antigen-specific cytotoxic activity, it is preferable that the γδ T cells obtained by the method of the present invention express a CAR. Confirmation that the cells have cytotoxic activity can be evaluated by known methods, and a suitable method is, for example, a method of measuring cytotoxic activity against cells expressing the target antigen of CAR by chromium release assay or the like.

[0084] In the present invention, the term "chimeric antigen receptor (CAR)" refers to a fusion protein comprising an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain. The antigen-binding domain of the CAR comprises a single-chain antibody (scFv) in which the light chain (VL) and heavy chain (VH) of the variable region of an antibody are linked in series via a spacer such as a linker (e.g., a linker consisting of G and S (GS linker) (e.g., GGGS, GGGGS, or a linker combining these (e.g., SEQ ID NO: 4 or 5, etc.)). After recognizing an antigen with the scFV region, a γδ T cell expressing a CAR transmits the recognition signal into the T cell through the intracellular signaling domain. By introducing a CAR into a γδ T cell, it is possible to confer specificity for a target antigen. In addition, since the CAR can directly recognize an antigen molecule independent of HLA class I or class II, it is possible to cause a strong immune response even against cells with reduced expression of HLA class I or class II genes. The antigen targeted by the CAR can be the same as the above-mentioned antigen targeted by the TCR.

[0085] Examples of the transmembrane domain of CAR include, but are not limited to, transmembrane domains derived from one or more proteins selected from the group consisting of TCR α, β or ζ chains, CD28, CD3ε chain, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, 4-1BB (CD137) and CD154. The transmembrane domain of the molecule from which the first intracellular signaling domain linked to the antigen binding domain is derived may be used, for example, when the molecule from which the first intracellular signaling domain linked to the antigen binding domain is derived is CD28, the transmembrane domain may also be derived from CD28. Alternatively, an artificially designed transmembrane domain may be used.

[0086] Examples of the intracellular signaling domain of CAR include, but are not limited to, intracellular domains derived from one or more proteins selected from the group consisting of CD3 ζ chain (TCR ζ chain), FcR γ chain, FcR β chain, CD3 γ chain, CD3 δ chain, CD3 ε chain, CD5, CD22, CD79a, CD79b and CD66d. Among these, the intracellular signaling domain derived from CD3 ζ chain is preferred. In addition, the intracellular signaling domain may further include an intracellular domain of a costimulatory molecule, and examples of such costimulatory molecules include, for example, an intracellular domain of one or more proteins selected from the group consisting of CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3 and CD83. By selecting the type and number of costimulatory molecules to be bound, the strength and duration of CAR activity can be controlled (e.g., Mol Ther. 2009;17:1453-1464.).

[0087] A spacer may be incorporated between the antigen-binding domain and the transmembrane domain of CAR, or between the intracellular signaling domain and the transmembrane domain of CAR, and the spacer may be a peptide usually consisting of 300 amino acids or less, preferably 10 to 100 amino acids, and most preferably 25 to 50 amino acids. Specific examples of the spacer include, but are not limited to, a hinge region derived from IgG1, and a peptide containing the CH2CH3 region of immunoglobulin and a part of CD3.

[0088] Specific examples of CARs include, but are not limited to, first-generation CARs in which an scFV and a CD3ζ chain are linked via a spacer; second-generation CARs in which a transmembrane domain and an intracellular domain derived from CD28 are incorporated between the scFV and CD3ζ chain of the first-generation CAR to enhance the activation ability of T cells; and third-generation CARs in which an intracellular domain of a costimulatory molecule other than CD28 (4-1BB or OX40) is incorporated between the intracellular domain of CD28 and the CD3ζ chain of the second-generation CAR.

[0089] More specifically, the CAR used in the present invention includes a chimeric antigen receptor that includes an scFv that recognizes CD19 as an antigen-binding domain, a transmembrane domain of CD8 as a transmembrane domain, and an intracellular domain derived from CD28, an intracellular domain derived from CD30, an intracellular domain derived from 4-1BB, and an intracellular domain derived from CD3ζ chain as an intracellular signaling domain. The order of the above-mentioned intracellular domains included in the intracellular signaling domain is not particularly limited, and is, for example, included in the order of the intracellular domain derived from CD28, the intracellular domain derived from CD30 or the intracellular domain derived from 4-1BB, and the intracellular domain derived from CD3ζ chain. More specifically, the chimeric antigen receptor of the present invention is, for example, an amino acid sequence represented by SEQ ID NO: 1 or 2, or an amino acid sequence represented by SEQ ID NO: 1 or 2 in which one or more amino acids (preferably about 1 to 100, preferably about 1 to 50, more preferably about 1 to 10, particularly preferably one to several (2, 3, 4, or 5)) have been substituted, deleted, added, and / or inserted.

[0090] Furthermore, the intracellular domain derived from CD30 may, for example, be an amino acid sequence in which one or more (preferably about 1 to 100, preferably about 1 to 50, more preferably about 1 to 10, particularly preferably one to several (2, 3, 4 or 5)) amino acids have been substituted, deleted, added and / or inserted in the amino acid sequence shown in SEQ ID NO: 3. When amino acids have been substituted, deleted, added and / or inserted as described above, the position of the substitution, deletion, addition and / or insertion is not particularly limited as long as the function of the intracellular domain of CD30 is maintained.

[0091] It can be confirmed by a known method that the above TCR and / or CAR (hereinafter sometimes abbreviated as "TCR, etc.") can specifically recognize and bind to an antigen, and suitable methods include, for example, a dextramer assay or an ELISPOT assay. By performing an ELISPOT assay, it can be confirmed that a T cell expressing a TCR, etc. on the cell surface recognizes a target antigen via the TCR, etc., and that the signal is transmitted into the cell.

[0092] Furthermore, the present inventors have found that cells expressing a fusion protein containing IL-15 and IL-15Rα together with the above-mentioned CAR (hereinafter sometimes abbreviated as "IL-15 / IL-15Rα") have increased cytotoxic activity compared to cells expressing only CAR. Therefore, from the viewpoint of cytotoxic activity, it is preferable that the γδ T cells obtained by the production method of the present invention express IL-15 / IL-15Rα, and more preferably, the above-mentioned CAR. Therefore, in order to obtain γδ T cells expressing IL-15 / IL-15Rα, the production method of the present invention may include a step of introducing a nucleic acid encoding IL-15 / IL-15Rα into cells obtained during either step (1) or (2) of 1 above (e.g., CD3 positive T cells obtained by step (2-2), CD3 positive T cells enriched by step (2-3), etc.).

[0093] In the IL-15 signal transduction system, IL-15Rα expressed on antigen-presenting cells usually binds to IL-15, and presents IL-15 to the IL-15 receptor consisting of IL-15Rβ and the common gamma chain (γc) on CD8-positive CD4-negative cells (trans-presentation), thereby maintaining the cytotoxic activity of CD8-positive CD4-negative cells. Therefore, when a CD3-positive cell expressing IL-15 / IL-15Rα is CD8-positive CD4-negative, the cell can transmit the IL-15 signal into its own cell via the IL-15 receptor. Alternatively, a CD3-positive cell expressing IL-15 / IL-15Rα can transmit the IL-15 signal into another CD8-positive CD4-negative cell via the IL-15 receptor. As described above, IL-15 / IL-15Rα can maintain the cytotoxic activity of CD8-positive CD4-negative cells, and therefore a continuous cytotoxic effect against cells targeted by CAR can be expected.

[0094] IL-15 / IL-15Rα may be a transmembrane protein or a secretory protein. It is known that the IL-15-binding domain of 1-65 amino acids from the N-terminus of the mature IL-15Rα is the region responsible for binding to IL-15 (Wei X. et al., J. Immunol., 167:277-282, 2001). Thus, the transmembrane protein may be a protein that has an IL-15-binding domain and a transmembrane domain of IL-15Rα. On the other hand, the secretory protein may be a protein that has an IL-15-binding domain and lacks the transmembrane domain of IL-15Rα (e.g., a protein consisting of 1-65 amino acid residues, 1-85 amino acid residues, or 1-182 amino acid residues of IL-15Rα, or a peptide containing an amino acid sequence that is 85% or more identical to said amino acid sequence).

[0095] IL-15 / IL-15Rα may incorporate a spacer between IL-15 and IL-15Rα, and the spacer may be a peptide usually consisting of 300 amino acids or less, preferably 10 to 100 amino acids, and most preferably 20 to 50 amino acids. Specific examples of the spacer include, but are not limited to, the above-mentioned GS linker.

[0096] IL-15 / IL-15Rα is not particularly limited as long as it is a protein in which IL-15 and IL-15Rα are fused, and specifically includes a peptide consisting of SEQ ID NO: 6. Alternatively, IL-15 / IL-15Rα is not particularly limited as long as it binds to an IL-15 receptor and transmits an IL-15 signal into cells, and specifically includes a peptide comprising an amino acid sequence having about 90% or more, preferably about 95% or more, more preferably about 97% or more, particularly preferably about 98% or more, and most preferably about 99% or more homology or identity with the amino acid sequence shown in SEQ ID NO: 6. Here, "homology" or "identity" refers to the ratio (%) of identical amino acids and similar amino acid residues (in the case of identity, identical amino acid residues) to all overlapping amino acid residues in the optimal alignment (preferably, the algorithm can take into account the introduction of gaps into one or both of the sequences for optimal alignment) when two amino acid sequences are aligned using a mathematical algorithm known in the art. "Similar amino acids" refer to amino acids that are similar in physicochemical properties, and examples of such amino acids include aromatic amino acids (Phe, Trp, Tyr), aliphatic amino acids (Ala, Leu, Ile, Val), polar amino acids (Gln, Asn), basic amino acids (Lys, Arg, His), acidic amino acids (Glu, Asp), amino acids with hydroxyl groups (Ser, Thr), and amino acids with small side chains (Gly, Ala, Ser, Thr, Met) that are classified into the same group. It is predicted that substitution with such similar amino acids will not cause a change in the phenotype of the protein (i.e., it is a conservative amino acid substitution). Specific examples of conservative amino acid substitutions are well known in the art and are described in various documents (see, for example, Bowie et al., Science, 247:1306-1310 (1990)).The homology or identity of amino acid sequences in this specification can be calculated using the homology calculation algorithm NCBI BLAST (National Center for Biotechnology Information Basic Local Alignment Search Tool) under the following conditions (expectation value = 10; gaps allowed; matrix = BLOSUM62; filtering = OFF).

[0097] The term "capable of binding" as used herein means "having an ability to bind" and refers to the ability to form a non-covalent complex with one or more other molecules. Various methods and assays for determining binding ability are known in the art. The binding is usually with high affinity, with an affinity measured by KD value preferably less than 1 μM, more preferably less than 100 nM, even more preferably less than 10 nM, even more preferably less than 1 nM, even more preferably less than 100 pM, even more preferably less than 10 pM, even more preferably less than 1 pM. The term "KD" or "KD value" is related to the equilibrium dissociation constant as known in the art.

[0098] The above TCR etc. are introduced into cells in the form of a nucleic acid encoding the TCR etc. A fusion protein containing IL-15 and IL-15Rα is also introduced into cells in the form of a nucleic acid encoding the fusion protein. The nucleic acid may be DNA or RNA, or may be a DNA / RNA chimera, but is preferably DNA. The nucleic acid may be double-stranded or single-stranded. If double-stranded, it may be double-stranded DNA, double-stranded RNA, or a DNA:RNA hybrid. If the nucleic acid is RNA, T in the RNA sequence is to be read as U. The nucleic acid may contain natural nucleotides, modified nucleotides, nucleotide analogs, or a mixture thereof, as long as it is capable of expressing a polypeptide in vitro or in a cell.

[0099] The above-mentioned nucleic acid can be constructed by a method known per se. For example, it is possible to construct a DNA encoding the full length or a part of a TCR or CAR by chemically synthesizing a DNA strand based on the amino acid sequence or nucleic acid sequence of a known TCR or CAR, or by connecting a partially overlapping oligo DNA strand synthesized using PCR or Gibson Assembly. Nucleic acids encoding fusion proteins containing IL-15 and IL-15Rα can also be constructed in the same manner.

[0100] The above nucleic acid can be incorporated into an expression vector. The vector can be a vector that is integrated into the genome of the target cell or a vector that is not integrated. In one embodiment, the vector that is not integrated into the genome can replicate outside the genome of the target cell. The vector can be present in multiple copies outside the genome of the target cell. In another embodiment of the present invention, the vector is integrated into the genome of the target cell. In a preferred embodiment, the vector is integrated into a predetermined location of the genome of the target cell.

[0101] Examples of promoters used in the above vectors include EF1α promoter, CAG promoter, SRα promoter, SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, RSV (Rous sarcoma virus) promoter, MoMuLV (moloney murine leukemia virus) LTR, HSV-TK (herpes simplex virus thymidine kinase) promoter, TCR Vα gene promoter, TCR Vβ gene promoter, etc. Among these, EF1α promoter, CAG promoter, MoMuLV LTR, CMV promoter, SRα promoter, etc. are preferred.

[0102] In addition to the promoter, the above vector may contain, if desired, transcriptional and translational regulatory sequences, ribosome binding sites, enhancers, replication origins, poly A addition signals, selection marker genes, etc. Examples of selection marker genes include dihydrofolate reductase gene, neomycin resistance gene, and puromycin resistance gene.

[0103] In one embodiment of the present invention, an expression vector containing a nucleic acid encoding a TCR α chain and a nucleic acid encoding a β chain can be introduced into a target cell to form a heterodimer of the TCR α chain and β chain in the target cell or on the cell surface. In this case, the nucleic acid encoding the TCR α chain and the nucleic acid encoding the β chain may be incorporated into separate expression vectors or into one expression vector. When incorporated into one expression vector, these two types of nucleic acids are preferably incorporated via a sequence that enables polycistronic expression. By using a sequence that enables polycistronic expression, it is possible to more efficiently express multiple genes incorporated into one type of expression vector. Examples of sequences that enable polycistronic expression include 2A sequences (e.g., 2A sequence (F2A) derived from foot-and-mouth disease virus (FMDV), 2A sequence (E2A) derived from equine rhinitis A virus (ERAV), 2A sequence (P2A) derived from porcine teschovirus (PTV-1), 2A sequence (T2A sequence) derived from Thosea asigna virus (TaV) (PLoS ONE 3, e2532, 2008, Stem Cells 25, 1707, 2007), and internal ribosome entry sites (IRES) (US Patent No. 4,937,190). From the viewpoint of uniform expression level, however, P2A and T2A sequences are preferred. The same applies when an expression vector containing a nucleic acid encoding a TCR gamma chain and a nucleic acid encoding a TCR delta chain is used.

[0104] The expression vector is not particularly limited as long as it can express TCR and the like for a period sufficient for disease prevention or treatment when introduced into cells, and examples thereof include virus vectors and plasmid vectors. Examples of virus vectors include retrovirus vectors (including lentivirus vectors and pseudotype vectors), adenovirus vectors, adeno-associated virus vectors, herpes virus vectors, Sendai virus, and episomal vectors. Transposon expression systems (PiggyBac systems) may also be used. Examples of plasmid vectors include animal cell expression plasmids (e.g., pa1-11, pXT1, pRc / CMV, pRc / RSV, pcDNAI / Neo), and the like.

[0105] The method of introducing the above nucleic acid or vector into a cell is not particularly limited, and any known method can be used. When introducing a nucleic acid or a plasmid vector, the same method as described in step 1.(1) above can be used. Alternatively, the above nucleic acid can be introduced into the genome of a cell by genome editing (e.g., CRISPR system, TALEN, ZFN, etc.).

[0106] The above-mentioned nucleic acid may also be directly introduced into cells in the form of RNA and used to express TCR etc. in the cells. As a method for introducing RNA, a known method can be used, and for example, the lipofection method, the electroporation method, etc. can be preferably used.

[0107] In the above steps (1) and (2), the timing of introducing the nucleic acid is not particularly limited as long as the introduced TCR and the like can be expressed in γδ T cells. For example, the timing of introducing the nucleic acid is not particularly limited as long as the introduced TCR and the like can be expressed in γδ T cells. + / CD43 + ), ProT cells (CD4 - / CD8 - ), CD3 + / CD4 + / CD8 + T cells, CD3 + / CD4 - / CD8 + T cells or other cells (e.g., CD3- / CD4 + / CD8 + The gene can be introduced at the stage of the gene expression vector (cell, etc.).

[0108] When the above-mentioned nucleic acid is introduced into a cell, it is preferable to suppress the expression of the endogenous TCR chain that the cell naturally expresses by using siRNA, from the viewpoint of increasing the expression of the introduced TCR, suppressing the appearance of mispaired TCR, or suppressing non-self-reactivity. When the above-mentioned nucleic acid is applied to the method, it is preferable to make the base sequence of the nucleic acid encoding the TCR a sequence different from the base sequence corresponding to the RNA on which the siRNA that suppresses the expression of the endogenous TCR chain acts (codon-converted sequence) in order to avoid the effect of siRNA on the TCR. These methods are described, for example, in International Publication No. 2008 / 153029. The above-mentioned base sequence can be prepared by introducing silent mutations into a nucleic acid encoding a TCR obtained from nature, or by chemically synthesizing an artificially designed nucleic acid. Alternatively, in order to avoid mispairing with the endogenous TCR chain, a part or all of the constant region of the nucleic acid encoding the introduced TCR may be replaced with a constant region derived from an animal other than human, for example, a mouse.

[0109] 2. γδ T cells or cell populations containing said γδ T cells The present invention also provides γδ T cells or a cell population comprising said γδ T cells, wherein said γδ T cells are cells differentiated from induced pluripotent stem cells derived from cells other than αβ T cells. The percentage of γδ T cells contained in the cell population (number of γδ T cells contained in said cell population / total number of cells contained in said cell population) is preferably 90% or more (e.g., 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100%). Such a cell population can be obtained, for example, by the method of the present invention. The percentage can be calculated by measuring the percentage of cells expressing γTCR, δTCR, and CD3 by flow cytometry. Thus, in one embodiment, the present invention provides γδ T cells produced by the method of the present invention and / or a cell population comprising said γδ T cells. The γδ T cells may contain a nucleic acid encoding an exogenous TCR, a nucleic acid encoding a CAR, and / or a nucleic acid encoding a fusion protein comprising IL-15 and IL-15Rα, as described in 1 above. The γδ T cells mentioned herein, or a cell population containing the γδ T cells, may hereinafter be abbreviated as "the cells, etc. of the present invention."

[0110] 3. Medicines containing the cells of the present invention The present invention provides a pharmaceutical comprising the cells of the present invention as an active ingredient (hereinafter, sometimes referred to as the "pharmaceutical of the present invention"). The cells of the present invention can exhibit cytotoxic activity against, for example, cancer cells, cancer stem cells, tumor cells, etc., and thus the pharmaceutical comprising the cells of the present invention can be used for the prevention or treatment of tumors such as cancer, and can be administered to, for example, mammals (e.g., mice, rats, hamsters, rabbits, cats, dogs, cows, sheep, monkeys, and humans), preferably humans. Thus, in one aspect of the present invention, the cells of the present invention are provided for use in the prevention or treatment of tumors. Also provided is a method for preventing or treating tumors, which includes administering the cells of the present invention, preferably in the form of a pharmaceutical comprising the cells.

[0111] Tumors such as cancer that can be prevented or treated by the pharmaceutical agent or the cells of the present invention are described in, for example, "Daniel Baumhoer et al., Am J. Clin Pathol, 2008, 129, 899-906," and tumors include benign tumors, malignant tumors (also referred to as "cancer"), and tumors that can be diagnosed or determined as benign or malignant. Specific examples of tumors include, but are not limited to, liver cancer (e.g., hepatocellular carcinoma), ovarian cancer (e.g., ovarian clear cell adenocarcinoma), childhood cancer, lung cancer (e.g., squamous cell carcinoma, small cell lung carcinoma), testicular cancer (e.g., non-seminomatous germ cell tumor), soft tissue tumor (e.g., liposarcoma, malignant fibrous histiocytoma), uterine cancer (e.g., cervical intraepithelial neoplasia, cervical squamous cell carcinoma), melanoma, adrenal tumor (e.g., adrenal adenoma), neural tumor (e.g., Schwannoma), gastric cancer (e.g., gastric adenocarcinoma), kidney cancer (e.g., Grawitz tumor), breast cancer (e.g., invasive lobular carcinoma, mucinous carcinoma), thyroid cancer (e.g., medullary carcinoma), laryngeal cancer (e.g., squamous cell carcinoma), and bladder cancer (e.g., invasive transitional cell carcinoma).

[0112] The cells contained in the pharmaceutical of the present invention may be cultured and / or stimulated using an appropriate medium and / or stimulatory molecules before administration to a subject. Examples of stimulatory molecules include, but are not limited to, cytokines, appropriate proteins, and other components. Examples of cytokines include IL-2, IL-7, IL-12, IL-15, IFN-γ, etc., and preferably IL-2 can be used. The concentration of IL-2 in the medium is not particularly limited, but is preferably 0.01 U / ml to 1×10 5 U / ml, more preferably 1 U / ml to 1×10 4U / ml. Examples of suitable proteins include CD3 ligand, CD28 ligand, and anti-IL-4 antibody. In addition, lymphocyte stimulating factors such as lectin can also be added. Furthermore, serum or plasma may be added to the medium. The amount of these to be added to the medium is not particularly limited, but is exemplified as 0% by volume to 20% by volume, and the amount of serum or plasma used can be changed depending on the culture stage. For example, the serum or plasma concentration can be reduced stepwise. The serum or plasma may be derived from either autologous or non-autologous sources, but from the viewpoint of safety, it is preferable to use autologous sources.

[0113] The pharmaceutical agent of the present invention is preferably administered parenterally to a subject. Parenteral administration methods include intravenous, intraarterial, intramuscular, intraperitoneal, and subcutaneous administration. The dosage is appropriately selected depending on the condition, weight, age, etc. of the subject, but usually, the number of cells is 1×10 per administration for a subject weighing 60 kg. 6 ~1×10 10 Preferably 1×10 7 ~1×10 9 10, more preferably 5×10 7 ~5×10 8 The pharmaceutical composition of the present invention is administered so that the number of cells is one. The pharmaceutical composition may be administered once or multiple times. The pharmaceutical composition of the present invention may be in a known form suitable for parenteral administration, such as an injection or infusion. The pharmaceutical composition of the present invention may contain a pharmacologically acceptable excipient as appropriate. The pharmaceutical composition of the present invention may contain physiological saline, phosphate buffered saline (PBS), a medium, etc., in order to stably maintain the cells. The medium is not particularly limited, but includes, but is not limited to, RPMI, AIM-V, X-VIVO10, and the like. In addition, the pharmaceutical composition may contain a pharmacologic acceptable carrier (e.g., human serum albumin), a preservative, etc., for the purpose of stabilization.

[0114] Furthermore, since the cells etc. of the present invention can kill cells expressing target antigens such as the above-mentioned tumor antigens, they can be used as a killing agent for cells expressing the antigens (e.g., cancer cells, cancer stem cells, tumor cells, etc.). Such killing agents can be prepared and used in the same manner as the above-mentioned pharmaceuticals.

[0115] The present invention also includes an embodiment of using the cells of the present invention in the manufacture of a tumor preventive or therapeutic agent, similar to a pharmaceutical comprising the cells of the present invention. The tumor preventive or therapeutic agent can be manufactured by a method known per se. For example, it can be manufactured in a known form suitable for parenteral administration, such as an injection or infusion, in the same manner as the above-mentioned method for preparing the pharmaceutical of the present invention.

[0116] The present invention will be described in more detail with reference to the following examples, but the scope of the present invention is not limited to these examples. EXAMPLES

[0117] [Example 1] Examination of a method for producing cells expressing γδTCR As a cell population containing hematopoietic progenitor cells, we used a suspension cell population that was differentiated from iPS cells (Ff-I01s04 line: derived from peripheral blood mononuclear cells of healthy individuals) provided by the Center for iPS Cell Research and Application, Kyoto University, according to a known method (e.g., the method described in Cell Reports 2 (2012) 1722-1735 and International Publication No. 2017 / 221975). Specifically, the Ff-I01s04 line was cultured at 3 x 10 in a 6-well plate treated with ultra-low adhesion. 5The cells were seeded at 100 cells / well (Day 0) and cultured in EB medium (StemPro34 supplemented with 10 μg / ml human insulin, 5.5 μg / ml human transferrin, 5 ng / ml sodium selenite, 2 mM L-glutamine, 45 mM α-monothioglycerol, and 50 μg / ml ascorbic acid 2-phosphate) supplemented with 10 ng / ml BMP4, 50 ng / ml bFGF, 15 ng / ml VEGF, and 2 μM SB431542 under hypoxic conditions (5% O2) for 5 days (Day 5). Next, 50 ng / ml SCF, 30 ng / ml TPO, and 10 ng / ml FLT-3L were added, and the cells were cultured for another 5 to 9 days (~Day 14) to obtain a floating cell population. During the culture period, the medium was replaced every 2 or 3 days. The above-mentioned floating cell population containing HPCs was stained with the following antibody set.

[0118] [Table 1]

[0119] The cell population stained as above was subjected to sorting by FACSAria. The obtained cell fraction was differentiated into lymphoid cells according to a known method (for example, the method described in Journal of Leukocyte Biology 96 (2016) 1165-1175 and International Publication No. 2017 / 221975). Specifically, the hematopoietic progenitor cell population was seeded at 2000 cells / well on a 48-well plate coated with Recombinant h-DLL4 / Fc chimera (SinoBiological) and Retronectin (Takara Bio), and cultured under 5% CO2 and 37°C conditions. The medium was replaced every 2 or 3 days during the culture period. The medium used was αMEM supplemented with 15% FBS, 2 mM L-glutamine, 100 U / ml penicillin, 100 ng / ml streptomycin, 55 μM 2-mercaptoethanol, 50 μg / ml ascorbic acid 2-phosphate, 10 μg / ml human insulin, 5.5 μg / ml human transferrin, 5 ng / ml sodium selenite, 50 ng / ml SCF, 50 ng / ml IL-7, 50 ng / ml FLT-3L, 100 ng / ml TPO, 15 μM SB203580, and 30 ng / ml SDF-1α. On days 7 and 14, the cells were subcultured onto similarly coated 48-well plates. On day 21 (Day 35), all cells were harvested, and the presence of CD45(+) and CD3(+) fractions was confirmed using a flow cytometer (BD FACSAria). TMThe cells were confirmed to be resistant to IL-15 (Fusion, BD Biosciences). The obtained cells were seeded in 24-well plates and cultured under 5% CO2 and 37°C conditions. The medium used was αΜΕΜ medium containing 15% FBS, 2 mM L-glutamine, 100 U / ml penicillin, 100 ng / ml streptomycin, 50 μg / ml ascorbic acid 2-phosphate, 10 μg / ml human insulin, 5.5 μg / ml human transferin, 5 ng / mL sodium selenite, 500 ng / mL anti-CD3 antibody (0KT3), 10 nM dexamethasone (Fuji Pharma Co., Ltd.: 10171-H02H), 100 U / ml IL-2, and 10 ng / mL IL-7. On day 27 (Day 41) after the start of culture, all cells were harvested, the cell numbers were counted using a hemocytometer, and then stained with the following antibody set.

[0120] [Table 2]

[0121] The staining results showed that cells expressing γδTCR (γδTCR positive cells) could be prepared from hematopoietic progenitor cells derived from iPS cells (Ff-I01s04 line) (Figure 1).

[0122] Furthermore, the γδTCR-positive cells included Vδ1-positive γδT cells and Vδ2-positive γδT cells, demonstrating that Vδ1-type and Vδ2-type γδT cells can be prepared (Figure 2).

[0123] [Example 2] Examination of cytotoxic activity of γδT cells The cytotoxic activity of γδ T cells derived from iPS cells (Ff-I01s04 strain) obtained in [Example 1] was evaluated. Mesothelioma cell line NCI-H226 was used as the target cells, and DELFIA BATDA Reagent (Perkin Elmer) was reacted at 37°C for 30 minutes. After washing the reaction solution, a cell population of γδ T cells derived from iPS cells (Ff-I01s04 strain) containing Vδ1-positive γδ T cells and Vδ2-positive γδ T cells was mixed at a ratio of 0.5, 1, 2, 4, 8, and 16 times the target cells, and the cytotoxic activity of γδ T cells derived from iPS cells (Ff-I01s04 strain) was evaluated based on the target cell death after 2 hours.

[0124] The evaluation results showed that iPS cell (Ff-I01s04 line)-derived γδ T cells had cytotoxic activity against the tumor cell line NCI-H226 (Figure 3).

[0125] (Expansion and functional evaluation of iγδT cells) [Example 3] Production of iγδT cells iPS cell (Ff-I01s04 line)-derived γδ T cells (iγδ T cells) were produced in the same manner as in Example 1, except that UCHT1 (GeneTex) was used as the anti-CD3 antibody.

[0126] [Example 4] Expansion of iγδT cells The iγδT cells obtained in [Example 3] were suspended at 2,000,000 cells / mL in α-MEM medium containing 15% FBS and the additives containing the cytokines in Table 3, seeded on a plate on which anti-CD3 antibody (UCHT1) and retronectin were immobilized, and cultured for 3 days under 5% CO2 / 37°C. On the third day of culture, the cells were collected from the plate and the cell count was measured using a NucleoCounter (registered trademark) NC-200 (ChemoMetec), and an appropriate amount of the cells were suspended in a medium containing α-MEM medium containing 15% FBS and the additives containing the cytokines in Table 4, added to a non-immobilized G-Rex (registered trademark) 6-well plate (WILSONWOLF), and cultured under 5% CO2 / 37°C. Thereafter, some of the cells were collected from the plate 4-6 times on the 5th, 6th, 7th, 8th, 9th, 10th, 11th, 14th, and 17th days of culture, and the cell count was measured using a hemocytometer. Anti-CD3 antibody and Retronectin were immobilized on the culture plate as follows: Anti-CD3 antibody (UCHT1, final concentration 3000 ng / mL) and Retronectin (final concentration 150 μg / mL) dissolved in PBS at the required concentration were added to the plate, and the plate was left to stand overnight at 4°C. After washing with PBS, the plate was used for the test.

[0127] [Table 3]

[0128] [Table 4]

[0129] Stimulation with anti-CD3 antibody (UCHT1) and anti-CD30 antibody induced proliferation of iγδT cells (FIG. 4).

[0130] [Example 5] Production of iPS cell-derived Vγ9Vδ2 T cells 1. iPS Cell Preparation The iPS cells used were the Ff-I01s04 strain provided by the Center for iPS Cell Research and Application (CiRA) of Kyoto University, as in Example 1. The iPS cells were cultured according to the protocol "Feeder-free culture of human iPS cells" distributed by CiRA.

[0131] 2. Differentiation of iPS cells into HPCs Differentiation of iPS cells into hematopoietic progenitor cells (HPCs) was carried out according to a known method (WO2017 / 221975), as in [Example 1].

[0132] 3. Vγ9Vδ2 gene The Vγ9Vδ2 T cell receptor (Vγ9Vδ2TCR G115) derived from the G115γδT cell clone was used. As a nucleic acid containing a gene encoding Vγ9Vδ2TCR G115, an oligo DNA encoding a polypeptide (SEQ ID NO: 7) designed to be arranged in the order of Table 5 from the N-terminus was artificially synthesized.

[0133] [Table 5]

[0134] 4. Construction of retroviral vector carrying Vγ9Vδ2 gene The lentivirus vector used was pLVSIN-Ub, which was prepared by removing the sequence encoding the neomycin resistance gene from pLVSIN-CMV Neo (Clontech) and replacing the CMV promoter with a human ubiquitin promoter. The artificial oligo DNA synthesized in 3 of [Example 5] was integrated into the multicloning site of the pLVSIN-Ub retrovirus vector. This plasmid and Lenti-X (Clontech) were used. TM 293T cell line and Lenti-X TM Lentiviral vectors were produced using Packaging Single Shots (VSV-G).

[0135] 5. Generation of iPS cell-derived Vγ9Vδ2 T cells The retroviral vector carrying the Vγ9Vδ2 gene prepared in [Example 5] 4. was infected into the iPS cells prepared in [Example 5] 1. and the iPS cell-derived hematopoietic progenitor cells (HPCs) prepared in Example [Example 5] 2. As in [Example 1], these cells were differentiated into T cells according to a known method (WO2017 / 221975) to produce iPS cell-derived Vγ9Vδ2 T cells. 500 ng / mL UCHT1 (GeneTex) was used as the anti-CD3 antibody used in the differentiation process. (Hereinafter, iPS cell-derived Vγ9Vδ2 T cells generated from iPS cells will be referred to as “iγ9δ2 T cells,” and iPS cell-derived Vγ9Vδ2 T cells generated from iPS cell-derived HPCs will be referred to as “iHγ9δ2 T cells.”) The expression of CD3, γδ TCR, Vγ9, and Vδ2 on the cell membrane surface of the obtained iγ9δ2 T cells and iHγ9δ2 T cells was analyzed using a flow cytometer (BD FACSAria TM Fusion, BD Biosciences) (Figs. 5 and 6).

[0136] [Example 6] Production of iPS cell-derived anti-CD19-CAR / IL-15γδ T cells 1. Anti-CD19-CAR gene As a nucleic acid containing the anti-CD19-CAR gene, an oligo DNA encoding a polypeptide (sequence number 2) designed to be arranged in the order of Table 6 from the N-terminus was artificially synthesized.

[0137] [Table 6]

[0138] 2. Preparation of retroviral vector carrying anti-CD19-CAR gene [Example 6] The artificial oligo DNA synthesized in 1 was inserted into the multicloning site of the pMY retrovirus vector. A viral vector was produced using FRY-RD18 cells for producing retrovirus vectors.

[0139] 3.IL-15Rα / IL-15 gene As a nucleic acid containing the IL-15Rα / IL-15 gene, an oligoDNA encoding a polypeptide (SEQ ID NO: 6) designed to be arranged in the order of Table 7 from the N-terminus was artificially synthesized.

[0140] [Table 7]

[0141] 4. Construction of retroviral vector carrying IL-15Rα / IL-15 gene [Example 6] The artificial oligo DNA synthesized in 3. was inserted into the multicloning site of the pMY retrovirus vector. A viral vector was produced using FRY-RD18 cells for producing retrovirus vectors.

[0142] 5. Production of iPS cell-derived anti-CD19-CAR / IL-15γδ T cells The retroviral vector carrying the anti-CD19-CAR gene prepared in [Example 6] 2. and the retroviral vector carrying the IL-15Rα / IL-15 gene prepared in [Example 6] 4. were infected into the iγδT cells obtained in [Example 4] and the iHγ9δ2T cells prepared in [Example 5] 5. to prepare iPS cell-derived anti-CD19-CAR / IL-15γδT cells. (Hereinafter, the iPS cell-derived anti-CD19-CAR / IL-15γδT cells prepared from the iγδT cells will be referred to as "iCD19CAR / IL-15γδT cells," and the iPS cell-derived anti-CD19-CAR / IL-15γδT cells prepared from the iHγ9δ2T cells will be referred to as "iHCD19CAR / IL-15γ9δ2T cells.")

[0143] [Example 7] Expansion of iPS cell-derived anti-CD19-CAR / IL-15γδT cells 1. Expansion of iCD19CAR / IL-15γδT cells The iCD19CAR / IL-15γδT cells obtained in [Example 6] were expanded in the same manner as in [Example 4]. However, a medium containing an additive containing a cytokine in Table 8 instead of the additive containing a cytokine in Table 3, and a medium containing an additive containing a cytokine in Table 9 instead of the additive containing a cytokine in Table 4 were used.

[0144] [Table 8]

[0145] [Table 9]

[0146] Stimulation with anti-CD3 antibody (UCHT1) and anti-CD30 antibody resulted in proliferation of iCD19CAR / IL-15γδT cells (Figure 7).

[0147] 2. Expansion of iHCD19CAR / IL-15γ9δ2 T cells The iHCD19CAR / IL-15γ9δ2 T cells obtained in [Example 6] were expanded in the same manner as in [Example 7] 1. However, anti-human CD30 antibody was not added. Stimulation with anti-CD3 antibody (UCHT1) resulted in proliferation of iHCD19CAR / IL-15γ9δ2 T cells (Figure 8).

[0148] [Example 8] Examination of cytotoxic activity of iPS cell-derived anti-CD19-CAR / IL-15γδ T cells The cytotoxic activity of iCD19CAR / IL-15γδT cells and iHCD19CAR / IL-15γ9δ2T cells obtained in [Example 7] was evaluated. CD19-positive Raji cells and CD19-negative CCRF-CEN cells were used as target cells, and iCD19CAR / IL-15γδT cells or iHCD19CAR / IL-15γ9δ2T cells were mixed at a ratio of 0.5, 1, 2, 4, 8, and 16 times the target cells, and the cytotoxic activity of iCD19CAR / IL-15γδT cells and iHCD19CAR / IL-15γ9δ2T cells was evaluated based on the rate of target cell death after 2 hours.

[0149] The evaluation results showed that iCD19CAR / IL-15γδT cells and iHCD19CAR / IL-15γ9δ2T cells had cytotoxic activity against CD19-positive Raji cells but not against CD19-negative CCRF-CEN cells (Figures 9 and 10).

[0150] [Example 9] Effect of iCD19CAR / IL-15γδT cells on extending survival time 5x10 NOD / Shi-scid,IL-2RγKO (NOG) mice (Central Institute for Experimental Animals, female, 7-8 weeks old) 5 Nalm6 xenograft mice were generated by transplanting 100 cells of Nalm6 cells (ATCC) into the tail vein. Four days after transplantation, iCD19CAR / IL-15γδT cells (5×10 6 A suspension of 1000 cells (1000 cells) in 0.1 mL of HBSS buffer or an equivalent volume of HBSS buffer (control) was administered via the tail vein, and the survival time was then determined. In mice that received CD19-positive Nalm6 cancer cells via the tail vein, all mice in the control group died within 3 weeks, whereas all mice in the iCD19CAR / IL-15γδT cell group survived for at least 6 weeks (Figure 11).

[0151] [Example 10] In vivo antitumor effect of iHCD19CAR / IL-15γ9δ2 T cells 5x10 NOD / Shi-scid,IL-2RγKO (NOG) mice (Central Institute for Experimental Animals, female, 7-8 weeks old) 5 Luciferase-expressing Nalm6 cells (ATCC) were transplanted into the tail vein to generate luciferase-expressing Nalm6 xenograft mice. Four days after transplantation, the iHCD19CAR / IL-15γ9δ2 T cells (5×10 6 A suspension of Nalm6 cells (1000 cells) in 0.1 mL of HBSS-buffer or an equal volume of HBSS-buffer (control) was administered via the tail vein. Two weeks after administration, luciferin was administered via the tail vein, and the activity of luciferase expressed by Nalm6 cells was measured using an IVIS Imaging System (IVIS LUMINA II, CaliperLS). In the control administration group, luminescence derived from Nalm6 cells was confirmed throughout the body, whereas in the iHCD19CAR / IL-15γ9δ2 T cell administration group, almost no luminescence was detected (Figure 12). [Industrial Applicability]

[0152] INDUSTRIAL APPLICABILITY According to the present invention, γδ T cells can be efficiently obtained, and the cells thus obtained are useful for preventing or treating diseases such as tumors.

[0153] This application is based on Japanese Patent Application No. 2018-133727 (filing date: July 13, 2018) and Japanese Patent Application No. 2019-117891 (filing date: June 25, 2019) filed in Japan, the contents of which are incorporated in their entirety by reference herein.

Claims

1. A method for producing γδ T cells from induced pluripotent stem cells derived from cells other than αβ T cells, comprising the following steps (1) and (2), wherein the γδ T cells are CD8α+β+ cells: (1) Establishment of induced pluripotent stem cells from cells other than αβ T cells (2) Differentiating the induced pluripotent stem cells established in step (1) into T cells.

2. The method of claim 1, wherein the cell other than an αβ T cell is a mononuclear cell other than an αβ T cell.

3. The method of claim 1 or 2, wherein the cell other than an αβ T cell is a monocyte.

4. The cells obtained in any one of steps (1) and (2) above are treated with a method for detecting and binding to a tumor-specific antigen or a tumor-associated antigen. (i) a nucleic acid encoding an αTCR and a nucleic acid encoding a βTCR; (ii) a nucleic acid encoding a γTCR and a nucleic acid encoding a δTCR, and / or (iii) a nucleic acid encoding a CAR The method according to any one of claims 1 to 3, comprising the step of introducing

5. The method of claim 4, wherein the γTCR is Vγ9TCR and the δTCR is Vδ2TCR.

6. The method according to any one of claims 1 to 5, comprising a step of introducing a nucleic acid encoding a fusion protein comprising IL-15 and IL-15Rα into a cell obtained in any one of steps (1) and (2).

7. A γδ T cell derived from an artificial pluripotent stem cell derived from a cell other than an αβ T cell, wherein the γδ T cell is γδ TCR+ and CD8α+β+.

8. A γδ T cell produced by the method according to any one of claims 1 to 6.

9. The cell according to claim 7 or 8, wherein the cell other than an αβ T cell is a mononuclear cell other than an αβ T cell.

10. The cell according to any one of claims 7 to 9, wherein the cell other than an αβ T cell is a monocyte.

11. The cell of any one of claims 7 to 10, wherein the γδ T cell expresses Vγ9TCR and Vδ2TCR.

12. The cell of any one of claims 7 to 11, wherein the γδ T cell expresses a CAR.

13. The cell of any one of claims 7 to 12, wherein the γδ T cell expresses a fusion protein comprising IL-15 and IL-15Rα.

14. A cell population in which at least 90% or more of the total cells are γδ T cells, the γδ T cells being cells differentiated from induced pluripotent stem cells derived from cells other than αβ T cells, and being γδ TCR+ and CD8α+β+.

15. A medicament comprising a cell according to any one of claims 7 to 13 or a cell population according to claim 14.

16. The pharmaceutical composition according to claim 15 for use in the prevention or treatment of a tumor.

17. A cell-killing agent comprising a cell according to any one of claims 7 to 13 or a cell population according to claim 14.

18. A cell according to any one of claims 7 to 13 or a cell population according to claim 14 for use in the prevention or treatment of a tumor.

19. Use of the cell according to any one of claims 7 to 13 or the cell population according to claim 14 in the manufacture of a preventive or therapeutic agent for a tumor.